JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

REVOLUTION Medicines Inc

Closed

SectorHealthcare

54.31 1.63

Overview

Share price change

24h

Current

Min

54.31

Max

55.3

Key metrics

By Trading Economics

Income

-34M

-248M

Profit margin

-74.379

Employees

700

EBITDA

-24M

-261M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+39.63% upside

Market Stats

By TradingEconomics

Market Cap

3.2B

10B

Previous open

52.68

Previous close

54.31

News Sentiment

By Acuity

14%

86%

18 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

REVOLUTION Medicines Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 paź 2025, 18:13 UTC

Major Market Movers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

Peer Comparison

Price change

REVOLUTION Medicines Inc Forecast

Price Target

By TipRanks

39.63% upside

12 Months Forecast

Average 76.07 USD  39.63%

High 90 USD

Low 66 USD

Based on 17 Wall Street analysts offering 12 month price targets forREVOLUTION Medicines Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

17 ratings

17

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

40.67 / 41.96Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

18 / 371 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat